GR72121B - - Google Patents

Info

Publication number
GR72121B
GR72121B GR63267A GR800163267A GR72121B GR 72121 B GR72121 B GR 72121B GR 63267 A GR63267 A GR 63267A GR 800163267 A GR800163267 A GR 800163267A GR 72121 B GR72121 B GR 72121B
Authority
GR
Greece
Application number
GR63267A
Other languages
Greek (el)
Inventor
Rechard Anthony Godwin Smith
John Gordon Winchester
Original Assignee
Beecham Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd
Publication of GR72121B publication Critical patent/GR72121B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR63267A 1979-11-05 1980-11-03 GR72121B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7938279 1979-11-05

Publications (1)

Publication Number Publication Date
GR72121B true GR72121B (enExample) 1983-09-16

Family

ID=10508982

Family Applications (1)

Application Number Title Priority Date Filing Date
GR63267A GR72121B (enExample) 1979-11-05 1980-11-03

Country Status (18)

Country Link
US (1) US4808405A (enExample)
EP (1) EP0028489B1 (enExample)
JP (1) JPS5678590A (enExample)
AR (1) AR224786A1 (enExample)
CA (1) CA1174621A (enExample)
CS (2) CS391191A3 (enExample)
DE (1) DE3065190D1 (enExample)
DK (1) DK158994C (enExample)
ES (1) ES8204467A1 (enExample)
GR (1) GR72121B (enExample)
HK (1) HK65886A (enExample)
HU (1) HU185223B (enExample)
IE (1) IE50174B1 (enExample)
IL (1) IL61408A (enExample)
NL (1) NL930029I2 (enExample)
NO (1) NO163867C (enExample)
NZ (1) NZ195469A (enExample)
ZA (1) ZA806641B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091240B1 (en) * 1982-04-07 1985-12-27 Beecham Group Plc Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them
WO1984001960A1 (en) * 1982-11-11 1984-05-24 Beecham Group Plc Pharmaceutically active compounds
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5231006A (en) * 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
JPH0296536A (ja) * 1988-09-29 1990-04-09 Green Cross Corp:The プラスミノゲン乾燥製剤
WO1990013640A1 (en) * 1989-05-01 1990-11-15 The University Of Notre Dame Du Lac Methods and materials for expression of human plasminogen in a eukaryotic cell system
EP0397366A1 (en) * 1989-05-09 1990-11-14 The Board Of Regents Of The University Of Oklahoma Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same
EP0472657B1 (en) * 1989-05-17 1996-03-13 Research Corporation Technologies, Inc. Method and composition for the treatment of thrombosis in a mammal
AU6470590A (en) 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5190756A (en) * 1989-12-01 1993-03-02 Genentech, Inc. Methods and materials for expression of human plasminogen variant
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
GB8928163D0 (en) * 1989-12-13 1990-02-14 Beecham Group Plc Novel treatment
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5187069A (en) * 1990-08-06 1993-02-16 Henry Ford Health System Active site labelling of plasminogen
WO1992018139A1 (en) * 1991-04-09 1992-10-29 Brigham And Women's Hospital Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
IL133526A0 (en) 1997-06-19 2001-04-30 Du Pont Pharm Co Inhibitors of factor xa with a neutral p1 specificity group
WO2001009188A1 (en) * 1999-07-29 2001-02-08 Dyax Corp. Binding moieties for fibrin
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
KR20010000669A (ko) * 2000-10-12 2001-01-05 김기환 스트렙토키나제와 사람 혈청알부민의 포합체를유효성분으로 함유하는 전신투여용 지속성 혈전 용해제
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
CN110894196A (zh) 2001-09-21 2020-03-20 百时美-施贵宝控股爱尔兰无限公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
US7645778B2 (en) 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
AR056867A1 (es) 2005-06-27 2007-10-31 Bristol Myers Squibb Co Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
ATE485269T1 (de) 2005-06-27 2010-11-15 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
US7816382B2 (en) 2005-06-27 2010-10-19 Bristol-Myers Squibb Company Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition
JP2009539873A (ja) 2006-06-08 2009-11-19 ブリストル−マイヤーズ スクイブ カンパニー 抗凝固剤として有用な第ＶＩＩａ因子インヒビターとしての２−アミノカルボニルフェニルアミノ−２−フェニルアセトアミド類
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
WO2008076805A2 (en) 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
AU2008266228A1 (en) 2007-06-13 2008-12-24 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
CA2724430A1 (en) 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
EP2534152B1 (en) 2010-02-11 2018-05-02 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
CN103974938B (zh) 2011-10-14 2016-11-09 百时美施贵宝公司 作为因子xia抑制剂的经取代的四氢异喹啉化合物
IN2014CN02805A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
SG11201401531RA (en) 2011-11-11 2014-07-30 Pfizer 2-thiopyrimidinones
PE20142164A1 (es) 2012-04-06 2014-12-27 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
SG11201500270RA (en) 2012-08-03 2015-03-30 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
US9409908B2 (en) 2012-08-03 2016-08-09 Bristol-Myers Squibb Company Dihydropyridone p1 as factor XIa inhibitors
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
JP6348582B2 (ja) 2013-10-09 2018-06-27 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
NO2760821T3 (enExample) 2014-01-31 2018-03-10
SG11201606779RA (en) 2014-03-17 2016-10-28 Pfizer Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
NO2721243T3 (enExample) 2014-10-01 2018-10-20
BR112017022340A2 (pt) 2015-05-05 2018-07-10 Pfizer 2-tiopirimidinonas
BR112017026191B1 (pt) 2015-06-17 2023-10-10 Pfizer Inc Compostos tricíclicos inibidores de fosfodiesterase, sua composição farmacêutica e uso dos mesmos
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
JP6785838B2 (ja) 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 新規な置換グリシン誘導のｆｘｉａ阻害剤
EP3858825A1 (en) 2015-08-27 2021-08-04 Pfizer Inc. Bicyclic-fused heteroaryl compounds as irak4 modulators
KR20180117156A (ko) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
AU2019329884B2 (en) 2018-08-31 2022-01-27 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
EP4578460A3 (en) 2019-05-20 2025-08-27 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CA3189771A1 (en) 2020-07-22 2022-01-27 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US20250066337A1 (en) 2021-08-26 2025-02-27 Pfizer Inc. Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178368A (en) * 1971-09-30 1979-12-11 Behringwerke Aktiengesellschaft Method for the treatment of thromboembolism
JPS5325775A (en) * 1976-08-24 1978-03-09 Miller Fluid Power Corp Module type fluid flow control element
US4082612A (en) * 1976-09-24 1978-04-04 Michael Reese Research Foundation Plasminogen activator complex
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions

Also Published As

Publication number Publication date
HK65886A (en) 1986-09-12
DK468880A (da) 1981-05-06
DK158994B (da) 1990-08-13
US4808405A (en) 1989-02-28
IE50174B1 (en) 1986-02-19
DE3065190D1 (en) 1983-11-10
DK158994C (da) 1991-01-07
IL61408A0 (en) 1980-12-31
IL61408A (en) 1983-10-31
EP0028489B1 (en) 1983-10-05
AU534017B2 (en) 1983-12-22
IE802277L (en) 1981-05-05
JPS5678590A (en) 1981-06-27
NO803304L (no) 1981-05-06
NL930029I1 (nl) 1993-06-01
CS391991A3 (en) 1992-06-17
JPH0316114B2 (enExample) 1991-03-04
ES496586A0 (es) 1982-05-01
NO163867B (no) 1990-04-23
NL930029I2 (nl) 1993-12-01
HU185223B (en) 1984-12-28
NO163867C (no) 1990-08-01
NZ195469A (en) 1984-05-31
AU6401180A (en) 1981-05-14
CS391191A3 (en) 1992-08-12
AR224786A1 (es) 1982-01-15
EP0028489A1 (en) 1981-05-13
ES8204467A1 (es) 1982-05-01
ZA806641B (en) 1981-10-28
CA1174621A (en) 1984-09-18

Similar Documents

Publication Publication Date Title
FR2447045B1 (enExample)
GR72121B (enExample)
FR2449895B1 (enExample)
FR2448005B1 (enExample)
FR2449149B1 (enExample)
FR2446178B1 (enExample)
FR2449689B1 (enExample)
FR2450425B3 (enExample)
FR2449517B1 (enExample)
FR2448596B1 (enExample)
FR2450670B2 (enExample)
FR2448523B1 (enExample)
AU79826S (enExample)
AU78391S (enExample)
AU78569S (enExample)
AU78386S (enExample)
AU77669S (enExample)
AU78271S (enExample)
AU77763S (enExample)
AU78270S (enExample)
AU78385S (enExample)
AU80228S (enExample)
AU79950S (enExample)
AU79918S (enExample)
AU78389S (enExample)